The Eye Report: Tackling Inflammation, Eyelid Margin Disease, and Corneal Nerve Health

Sunday, August 17, 2025
11:00AM - 2:00PM EDT
Synchronous Virtual

Join us for an educational and interactive virtual synchronous course providing optometrists with comprehensive education on etiology, diagnosis, and treatment options for the management of eyelid margin diseases, corneal nerve dysfunction, and other ocular inflammatory conditions.

During our Sunday Morning Newscast, attendees can expect to learn through real-time discussions, achieve implementable guidance drawn from case presentations, and participate in dynamic, real-time, interactive polling and discussions to test their knowledge and build their confidence and clinical acumen.

Don’t miss this chance to enhance your clinical practice while enjoying an engaging platform for knowledge exchange!

Faculty

Marc Bloomenstein, OD, FAAO

Schwartz Laser Eye Center,
Scottsdale, Arizona

Doug Devries, OD

Eye Care Associates of Nevada,
Sparks, Nevada

Lindsay Bull, OD, FAAO

Eye Care Associates of South Tulsa,
Oklahoma

Mitch Ibach, OD, FAAO

Vance Thompson Vision,
Sioux Falls, South Dakota

Cory J. Lappin, OD, MS, FAAO

Phoenix Eye Care,
Arizona

Agenda


11:00 AM ET	Welcome and Introduction
11:10 AM ET	Eyelid Margin Health Understanding Eyelid Margin Disease Diagnostics for Eyelid Margin Health Managing Eyelid Margin Disease Case Reports Interactive Polling and Case Challenges Q&A
12:30 PM ET	Corneal Nerve Dysfunction and Inflammation Causes and Impact Diagnostics and Best Practices for Corneal Nerve Health and Inflammation Treatment and Integration for Corneal Nerve Health Inflammation Chronic Ocular Surface Pain Interactive Polling and Case Challenges
1:50 PM ET	Conclusion and Key Takeaways Summary and key insights Interactive Polling Results Final Remarks

CE Information

COPE accreditation pending.

Learning Objectives

Review the underlying causes and risk factors contributing to meibomian gland dysfunction (MGD), Demodex blepharitis, inflammation, and corneal nerves in ocular surface disease (OSD).
Identify diagnostic tools and techniques used to assess eyelid margin health, inflammation, and corneal nerve integrity.
Examine current and emerging treatment options for managing eyelid margin health, inflammation, and corneal nerve health.
Develop strategies for discussing diagnosis, treatment options, and setting realistic expectations with patients.

Disclaimer
The objective of TFG in developing continuing medical education activities is to promote the free expression and interchange of ideas and information for educational purposes. TFG does not accept responsibility for any opinions, positions, or statements contained or expressed in such material, and such opinions, positions and statements are not necessarily those of the TFG. Courses are intended to provide instruction leading to new knowledge and/or skills. TFG does not certify competence upon completion of the courses. The information presented is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Financial Relationship Disclosures

Marc Bloomenstein, OD, Faculty and Planner, has the following relevant financial relationships. Consultant: AbbVie, Azura, Lenz, OcuSoft, Reichert, Sydnexis, Topcon and Visus. Consultant & Speaker: Alcon, Bausch+Lomb, and Tarsus. Speaker: Sun Pharma.

Doug Devries, OD, Planner, has the following relevant financial relationships. Consultant: AbbVie, Asecula, and SBH. Consultant & Speaker: Alcon, Bausch+Lomb, Bio Tissue, BlephEx, Brill, Dompe, Harrow, Lenz, Lumenis, Sun, and Tarsus. Speaker: ANI, Azura, Bruder, Malinckrocdt, and Tenpoint.

Lindsey Bull, OD, Faculty, has the following relevant financial relationships. Consultant & Speaker: Abbvie and Lenz. Dr. Bull has disclosed the following non-relevant financial relationship. Consultant: Viatris (relationship has ended).

Mitch Ibach, OD, Faculty, has the following relevant financial relationships. Consultant: Abbvie, Allergan, C-Light, ICare, Tarsus, and Thea. Consultant & Speaker: Alcon, Bausch+Lomb, Dompe, Glaukos, and Zeiss. Stock, Private Company: Balance Ophthalmics.

Cory Lappin, OD, Faculty, has the following relevant financial relationships. Advisory Board: Eyenovia, Harrow, Nordic Pharma, and Vital Tears. Advisory Board, Consultant, & Speaker: Alcon, Bausch+Lomb, Bruder, and Tarsus. Advisory Board, Consultant & Executive Team Member: Myze. Consultant: CSI Dry Eye Software, Ocubio, Rinsada, SCOPE Health, Inc., Sight Sciences, Tear Restore, and Viatris. Consultant, Medical Director: Norwood Device and Diagnostics. Consultant & Speaker: Lumenis, and PRN Vision Group. Consultant & Stock, Private Company: Barti and NuLids. Speaker: Dompe.

Laura Straub, Staff, has the following relevant financial relationships: Consultant: LaunchLab Partners, Powers and Company, MJM and Holliday Communications. Laura has disclosed the following non-relevant financial relationships. Consultant: Avisi Technologies, Nova Eye, Rayner, RxSight, STAAR Surgical and Zeiss (all relationships have ended).

All other Fundingsland Group staff, planners, reviewers, and writers have no financial relationships with ineligible companies.

All identified relevant financial relationships have been mitigated and the educational content thoroughly evaluated for fair, balanced, and safe, effective patient care.

This activity is supported by unrestricted educational grants from Dompé US, Inc., Johnson & Johnson Vision, Sun Pharmaceutical Industries, Inc. and Thea Pharma Inc.